Friday, July 10, 2026

Patent intelligence · US

US 12214045

Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods

granted A61KA61K47/54A61K47/60A61K47/642
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 423
Patent details — US 12214045
Jurisdiction
US
Status
granted
Grant date
Feb 4, 2025
Expiration
Jan 30, 2045
Claims
24
CPC classes
A61K, A61K47/54, A61K47/60, A61K47/642
View on Google Patents ↗

Quick answer

US 12214045 (Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods) is held by Nektar Therapeutics. Status: granted. Granted Feb 4, 2025. Expires Jan 30, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
24
CPC classes
A61K, A61K47/54, A61K47/60, A61K47/642, A61K9/0029, A61P

More from Nektar Therapeutics

Related pharmaceutical patents in our USPTO index.

  1. US 12324828

    Conjugates of a factor VIII moiety having an oxime-containing linkage

    Nektar Therapeutics · Expires Jun 5, 2045

    granted
  2. US 12325708

    Adenosine 2 receptor antagonists

    Nektar Therapeutics · Expires Jun 5, 2045

    granted
  3. US 12247059

    Conjugates of an IL-2 moiety and a polymer

    Nektar Therapeutics · Expires Mar 6, 2045

    granted
  4. US 12233104

    Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist

    Nektar Therapeutics · Expires Feb 20, 2045

    granted
  5. US 12054553

    Immunotherapeutic tumor treatment method

    Nektar Therapeutics · Expires Aug 1, 2044

    granted
  6. US 12036283

    Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

    Nektar Therapeutics · Expires Jul 11, 2044

    granted
  7. US 12030940

    Immunotherapeutic tumor treatment method

    Nektar Therapeutics · Expires Jul 4, 2044

    granted

Frequently asked questions

What is US patent 12214045?

US 12214045 (Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods) is held by Nektar Therapeutics. Status: granted. Granted Feb 4, 2025. Expires Jan 30, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12214045?

Nektar Therapeutics is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 423 pharmaceutical patents for this assignee.

When does US 12214045 expire?

Our index shows an expiration date of Jan 30, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.